

## IN THE CLAIMS

Please amend the claims as follows:

Please cancel claims 20, 24, 28, 29 and 32.

Please amend claims 17, 21, 30 and 31 as follows:

17. (Twice Amended) An injectable formulation, comprising:
- (a) particles comprising a biocompatible polymeric matrix, the matrix comprising a poly(lactide-co-glycolide);
  - (b) a biologically active polypeptide dispersed within the matrix; and
  - (c) an injection vehicle comprising hyaluronic acid;
- wherein the polypeptide is selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody.
21. (Amended) An injectable formulation, comprising:
- (a) hyaluronic acid; and
  - (b) particles, comprising:
    - (i) a polypeptide selected from the group consisting of a growth hormone, a hepatocyte growth factor (HGF), a vascular endothelial growth factor (VEGF), an anti-vascular endothelial growth factor Fab (anti-VEGF Fab), a glucagon-like peptide I (GLP-I), a nerve growth factor, an insulin-like growth factor, and an antibody; and
    - (ii) a biocompatible polymeric matrix.
30. (Amended) The injectable formulation of claim 21, wherein the concentration of the particles is about 1 mg/mL to about 500 mg/mL of formulation.
31. (Amended) The injectable formulation of claim 21, wherein the concentration of the particles is about 1 mg/mL to about 300 mg/mL of formulation.